Weight-loss version of smegalotide is officially launched in China

Novo Nordisk announced on November 17 that Novo Yinying, the world's first and currently the only weekly preparation of glucagon-like peptide-1 receptor agonist (GLP-1) for long-term weight management, has been officially launched in China. Novo Yinying (smeglutide injection for long-term weight management) can achieve an average weight loss of about 17%, and its weight loss effect can last for at least 2 years. Up to now, smeglutide has accumulated more than 22 million years of experience in patients with exposure.